Cargando…
Utilizing T(H)9 cells as a novel therapeutic strategy for malignancies
T(H)9 cells join the ever-growing list of CD4(+) T helper subsets and primarily mediate anti-parasite immune responses. We have recently demonstrated that tumor-specific T(H)9 cells induce a CCL20-CCR6-dependent regulation of DCs while stimulating CD8(+) T cell-mediated antitumor immunity. These fin...
Autores principales: | Lu, Yong, Yi, Qing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Landes Bioscience
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3661147/ https://www.ncbi.nlm.nih.gov/pubmed/23802062 http://dx.doi.org/10.4161/onci.23084 |
Ejemplares similares
-
Immune checkpoint blockade in malignant mesothelioma: A novel therapeutic strategy against a deadly disease?
por: Calabrò, Luana, et al.
Publicado: (2014) -
Anticancer Tc9 cells: Long-lived tumor-killing T cells for adoptive therapy
por: Lu, Yong, et al.
Publicado: (2014) -
The relationship between malignant and tumor-associated cells provides a new strategy for targeted diagnosis and therapy
por: Lu, Xiaoling, et al.
Publicado: (2013) -
Modulation of DNA repair genes induced by TLR9 agonists: A strategy to eliminate “altered” cells?
por: Sommariva, Michele, et al.
Publicado: (2012) -
TDG is a novel tumor suppressor of liver malignancies
por: Hassan, Haider M., et al.
Publicado: (2020)